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Abstract
Introduction Rheumatoid arthritis (RA) associates with
excessive cardiovascular morbidity and mortality, attributed to
both traditional and novel cardiovascular risk factors. The
metabolic syndrome, a cluster of classical cardiovascular risk
factors, including hypertension, obesity, glucose intolerance,
and dyslipidaemia, is highly prevalent in RA. Reports suggest
that long-term glucocorticoid (GC) use may exacerbate
individual cardiovascular risk factors, but there have been no
studies in RA to assess whether it associates with the metabolic
syndrome. We examined whether GC exposure associates with
the presence of metabolic syndrome in patients with RA.
Methods RA patients (n = 398) with detailed clinical and
laboratory assessments were categorised into three groups
according to GC exposure: no/limited (<3 months) exposure
(NE), low-dose (<7.5 mg/day) long-term exposure (LE), and
medium-dose (greater than or equal to 7.5 mg to 30 mg/day)
long-term exposure (ME). The metabolic syndrome was defined
using the National Cholesterol Education Programme III
guidelines. The association of GC exposure with the metabolic
syndrome was evaluated using binary logistic regression.
Results The metabolic syndrome was present in 40.1% of this
population and its prevalence did not differ significantly between
the GC exposure groups (NE 37.9% versus LE 40.7% versus
ME 50%, P  = 0.241). Binary logistic regression did not
demonstrate any increased odds for the metabolic syndrome
when comparing ME with LE (odds ratio = 1.64, 95%
confidence interval 0.92 to 2.92, P = 0.094) and remained non
significant after adjusting for multiple potential confounders.
Conclusions Long-term GC exposure does not appear to
associate with a higher prevalence of the metabolic syndrome in
patients with RA. The components of the metabolic syndrome
may already be extensively modified by other processes in RA
(including chronic inflammation and treatments other than GCs),
leaving little scope for additive effects of GCs.
Introduction
An association between rheumatoid arthritis (RA) and
increased cardiovascular disease burden has been recog-
nised for many years [1]. This results in excess mortality and
reduced lifespan compared with the general population [2,3].
Many factors may contribute to the increased cardiovascular
risk, including classical risk factors such as smoking, diabetes,
hypertension, and obesity and novel risk factors such as sys-
temic inflammation, a prothrombotic state, and hyperhomo-
cystinaemia [4].
Glucocorticoids (GCs) are known to have beneficial effects in
controlling rheumatoid inflammation [5,6] but their use has
been curbed due to their adverse effects. They are used
increasingly as a short-term measure to induce rapid reduction
in disease activity whilst awaiting the effects of slower acting
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disease-modifying anti-rheumatic drugs (DMARDs) [7]. Long-
term use of GCs is controversial due to an undesirable side
effect profile that includes dyslipidaemia [8], hyperglycaemia
[9], insulin resistance [10], hypertension [11,12], and central
obesity [11]: these may collectively contribute to the develop-
ment of the metabolic syndrome [13,14] and atherosclerosis
[15,16].
The metabolic syndrome, first described by Reaven in 1988
[17], is a cluster of classical cardiovascular risk factors (obes-
ity, glucose intolerance, dyslipidaemia, and hypertension)
thought to associate with cardiovascular risk beyond the sum
of its individual components [18], although this has recently
been questioned [19]. It is estimated that the metabolic syn-
drome affects 20% to 30% of the adult population in devel-
oped countries [20-22] but its prevalence varies according to
the definition used as well as environmental and genetic differ-
ences between populations [22]. As a consequence of physi-
cal inactivity and poor diet, rates of obesity and diabetes are
increasing worldwide [23,24], with an expected exponential
rise in the percentage of the population affected by the meta-
bolic syndrome [23]. The pathogenesis underlying the cluster-
ing of cardiovascular risk factors remains unclear: genetic
predisposition, obesity, and inflammation have been sug-
gested to be involved [25,26]. A recent study has shown that
patients with RA have a higher prevalence of metabolic syn-
drome than controls [27], although another study has demon-
strated an equally high prevalence between Mediterranean RA
patients and local general population controls [28]. In the
present cross-sectional study, we addressed the hypothesis
that RA patients receiving long-term GC will have an
increased prevalence of each of the individual components of
the metabolic syndrome (dyslipidaemia, hypertension, hyperg-
lycaemia, and central obesity) as well as the metabolic syn-
drome itself.
Materials and methods
RA patients (n = 398) fulfilling the revised American College
of Rheumatology criteria [29] were recruited from routine out-
patient clinics at the Department of Rheumatology, Dudley
Group of Hospitals NHS Trust (Dudley, West Midlands, UK).
Characteristics of the study population are shown in Table 1.
Local ethics committee approval was granted for the study
and all participants provided informed consent.
All patients underwent the same baseline evaluation prospec-
tively. The following details were recorded: basic demograph-
ics (that is, age, gender, height, weight, and waist
circumference), a full medical history (including specific
details regarding RA and cardiovascular disease), and current
disease activity and physical function, using the 28-joint dis-
ease activity score (DAS-28) [30] and health assessment
questionnaire (HAQ) [31], respectively. All current medica-
tions, including anti-rheumatic drugs, analgesics, and cardio-
vascular drugs such as statins or anti-hypertensives, were
documented. Information regarding GC (oral prednisolone)
dose and duration of exposure was recorded and categorised
into none or low-dose (<7.5 mg of prednisolone daily), limited
duration (<3 months) GC exposure (no exposure, NE), low-
dose long-term (>6 months) (low exposure, LE), or medium-
dose (prednisolone at least 7.5 to 30 mg daily for more than 6
months) long-term (medium exposure). There were no patients
exposed to high-dose long-term GC. Baseline blood samples,
including fasting lipid profiles (total cholesterol, triglycerides
(TGs), and high-density lipoproteins (HDLs)), erythrocyte sed-
imentation rate (ESR), C-reactive protein, fasting glucose,
insulin, and rheumatoid factor, were taken. All blood tests were
analysed by a single laboratory. The metabolic syndrome was
classified by National Cholesterol Education Programme III
(NCEP III) criteria [32]: fasting plasma glucose of at least 6.1
mmol/L or on drug treatment for elevated blood glucose,
systolic blood pressure of at least 130/85 mm Hg or on drug
treatment for elevated blood pressure, TG at least 1.7 mmol/L
or drug treatment for elevated TG, HDL in males of less than
1.0 mmol/L and in females of less than 1.3 mmol/L or on drug
treatment for a low HDL, and waist circumferences in males of
greater than 102 cm and in females of greater than 88 cm,
with the metabolic syndrome defined as the presence of at
least three of these criteria [32].
Analysis of the data was carried out using SPSS 14.0 (SPSS
Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was
used to evaluate the distribution of each parameter. Values
were expressed as mean ± standard deviation, median (25th–
75th percentile), or number (percentage), as appropriate.
Comparisons were performed by analysis of variance, Kruskal-
Wallis, and chi-square test for normally distributed, non-nor-
mally distributed, and categorical variables, respectively. To
evaluate the independence of the association between GC
exposure and the metabolic syndrome, binary logistic regres-
sion analysis was used.
Results
Descriptive characteristics of the population studied
Median (interquartile range) age in the total cohort was 63.08
(55.46 to 69.62) years, disease duration was 10 (4 to 18)
years, and 292 (73%) of the patients were female. Three hun-
dred forty patients (87.4%) were receiving DMARDs (two
thirds as monotherapy and the remaining as combination ther-
apy), of whom 225 (56.3%) were taking methotrexate, 118
(29.5%) sulphasalazine, 80 (20%) hydroxycholoroquine, 16
(4%) leflunomide, and 46 (11.5%) anti-tumour necrosis factor
(anti-TNF) biologics; 111 patients (27.8%) were on nonsteroi-
dal anti-inflammatory drugs or cyclooxygenase II inhibitors.
One third of the cohort, 117 patients (29.4%), were taking
GCs, with similar numbers in the LE and ME groups (58 ver-
sus 59 patients, respectively). Other drugs included statins in
83 (20.8%) and antihypertensives in 177 (44.5%) patients.
Further baseline characteristics of the study population are
described in detail in previous papers by our group [12,33].Available online http://arthritis-research.com/content/10/6/R145
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Table 1
Demographics and clinical and laboratory characteristics of the glucocorticoid exposure groups
NE (n = 281) LE (n = 58) ME (n = 59) P value
General demographics
Age, years 62 (53.03–68.56) 66.01 (59–71.47) 66.6 (60.7–71.6) 0.002
Gender female, number (percentage) 214 (76.2) 41 (70.7) 36 (61) 0.053
RA characteristics
RF-positive, number (percentage) 210 (76.4) 42 (73.7) 43 (75.4) 0.909
Anti-CCP-positive, number (percentage) 181 (67.5) 36 (63.2) 41 (73.2) 0.517
Disease duration, years 7 (3–15) 16 (10–25.5) 18 (10–39) <0.001
Disease activity
CRP, mg/L 8 (5–18) 8 (5–17) 9 (5–28) 0.421
ESR, mm/h 20 (10–38) 15.5 (6.75–29.25) 26 (12–45) 0.031
DAS-28 4.15 ± 1.38 4.09 ± 1.37 4.59 ± 1.47 0.080
Disease severity
HAQ 1.38 (0.5–2) 1.63 (0.72–2.16) 2.13 (1.63–2.5) <0.001
Extra-articular disease, number (percentage) 180 (64.1) 42 (72.4) 45 (76.3) 0.124
Joint replacement surgery, number (percentage) 65 (23.1) 21 (36.2) 29 (49.2) <0.001
Medications
Methotrexate, number (percentage) 161 (57.3) 35 (60.3) 28 (47.5) 0.305
Sulphasalazine, number (percentage) 96 (34.2) 11 (19) 11 (18.6) 0.009
Hydroxychloroquine, number (percentage) 57 (20.3) 13 (22.4) 10 (16.9) 0.754
Leflunomide, number (percentage) 11 (3.9) 1 (1.7) 4 (6.8) 0.374
Anti-TNF, number (percentage) 29 (10.3) 9 (15.5) 7 (11.9) 0.518
NSAIDS/COX II, number (percentage) 82 (29.2) 15 (25.9) 13 (22) 0.508
Risk factors for the MetS
Waist, cm 97.12 ± 12.39 97.35 ± 14.3 100.9 ± 15.19 0.172
Trigylcerides, mmol/L 1.2 (0.9–1.6) 1.2 (0.9–1.63) 1.4 (1.1–1.8) 0.010
Systolic blood pressure, mm Hg 140 (126.25–150) 142 (125.75–159) 145 (135–160) 0.022
Diastolic blood pressure, mm Hg 78.66 ± 10.85 79.97 ± 10.82 79.06 ± 13.06 0.716
HDL, mmol/L 1.5 (1.2–1.8) 1.7 (1.38–2.03) 1.7 (1.4–2) 0.011
LDL, mmol/L 5.2 ± 1.07 5.31 ± 1.27 5.25 ± 1.54 0.798
Criteria for MetS
Waist M, number (percentage) 163 (65.2) 32 (65.3) 36 (69.2) 0.853
Triglycerides M, number (percentage) 96 (34.2) 24 (41.4) 31 (52.5) 0.026
Hypertension M, number (percentage) 220 (78.3) 45 (77.6) 55 (93.2) 0.027
HDL M, number (percentage) 94 (33.5) 20 (34.5) 24 (40.7) 0.570
Fasting plasma glucose M, number (percentage) 38 (13.5) 9 (15.8) 14 (24.1) 0.125
Patients fulfilling criteria of MetS
NCEP, number (percentage) 105 (37.9) 22 (40.7) 28 (50.0) 0.241Arthritis Research & Therapy    Vol 10 No 6    Toms et al.
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Univariate analysis
Patients in the LE and ME groups were older (P = 0.002) and
had longer disease duration (P < 0.001) and higher ESR (P =
0.031) and HAQ (P < 0.001) and more frequent joint replace-
ment surgery (P < 0.001) than those in the NE group (Table
1). There were no significant differences between LE and ME.
Of the risk factors for the metabolic syndrome, TG, systolic
blood pressure, and HDL were all higher in patients receiving
long-term GCs (LE or ME). TGs were significantly higher in the
ME group (P = 0.010) compared with NE, but no significant
difference was noted between LE and NE. Systolic blood
pressure increased as GC exposure increased (NE 140
(126.25 to 150) mm Hg versus LE 142 (125.75 to 159) mm
Hg versus ME 145 (135 to 160) mm Hg, P = 0.022). Interest-
ingly, HDL levels were higher in the LE and ME groups (P =
0.011).
The individual components that comprise the metabolic syn-
drome were analysed to assess the proportion of patients in
each of the GC exposure groups fulfilling the NCEP III-defined
cut off levels. TG levels adequate for contributing as a compo-
nent of the metabolic syndrome were observed in a signifi-
cantly higher proportion of patients in the LE and ME groups
compared with NE (P = 0.026). The NCEP III cut off for hyper-
tension was present in a significantly higher proportion of
patients in the ME group (P = 0.027) but not in the LE group.
The other individual components that contribute to the defini-
tion of the metabolic syndrome (waist circumference, HDL,
and fasting plasma glucose) were observed in similar propor-
tions of patients within the NE, LE, and ME groups.
On combining the individual components to fulfil the NCEP III
criteria for the metabolic syndrome (presence of at least three
of the components), there was no evidence of a significant
association between the degree of GC exposure and the pres-
ence of the metabolic syndrome (NE 105 (37.9%) versus LE
22 (40.7%) versus ME 28 (50%), P = 0.241). Factors identi-
fied to be significantly associated with both the metabolic syn-
drome and GC exposure, thus acting as potential
confounders, included age (P = 0.001 and P = 0.002, respec-
tively), RA disease duration (P = 0.008 and P < 0.001), ESR
(P = 0.006 and P = 0.031), and HAQ (P = 0.036 and P <
0.001).
Multivariate analysis
The association between GC exposure and the frequency of
the metabolic syndrome was assessed using a logistic regres-
sion model (Table 2). The analysis did not demonstrate a sta-
tistically significant association between LE (odds ratio (OR)
= 1.13 (0.62 to 2.04), P = 0.695) or ME (OR = 1.64 (0.92 to
2.92), P = 0.094) and the metabolic syndrome in either the
crude model or following adjustment for all of the potential
confounders mentioned above (age, ESR, disease duration,
and HAQ; for completeness, gender was also added to the
model): LE OR = 1.15 (0.61 to 2.19) (P = 0.670) and ME OR
= 1.4 (0.72 to 2.58) (P = 0.340). For reasons of colinearity,
ESR and DAS could not be included in the same model. How-
Results expressed as number (percentage), median (25th–75th percentile), or mean ± standard deviation, as appropriate. Anti-CCP, anti-cyclic 
citrullinated peptide; anti-TNF, anti-tumour necrosis factor therapy; CRP, C-reactive protein; HAQ, health assessment questionnaire; DAS-28, 28-
joint disease activity score; ESR, erythrocyte sedimentation rate; Triglycerides M, triglycerides of at least 1.7 mmol/L or on drug treatment for 
elevated triglycerides; Waist M, waist circumference of greater than 102 cm in males and greater than 88 cm in females. Fasting plasma glucose 
M, fasting plasma glucose of at least 6.1 mmol/L or on drug treatment for elevated blood glucose; HDL, high-density lipoprotein; HDL M, high-
density lipoprotein level of less than 1.0 mmol/L in males or less than 1.3 mmol/L in females or on drug treatment for low HDL; Hypertension M, 
systolic blood pressure of at least 130/85 mm Hg or on antihypertensive medication; LDL, low-density lipoprotein; LE, low-dose/long-term 
exposure; ME, moderate-dose/long-term exposure; MetS, metabolic syndrome; NCEP, National Cholesterol Education Programme; NE, none/
limited exposure; NSAIDs/COX II, nonsteroidal anti-inflammatory drugs/cyclooxygenase II inhibitors; RA, rheumatoid arthritis; RF, rheumatoid 
factor;
Table 1 (Continued)
Demographics and clinical and laboratory characteristics of the glucocorticoid exposure groups
Table 2
Odds ratios for the metabolic syndrome (NCEP III) in comparison with the amount of steroid exposure
LD/LTE MD/LTE
OR (95% CI) P value OR (95% CI) P value
Crude 1.13 (0.62–2.04) 0.695 1.64 (0.92–2.92) 0.094
Model a 0.998 (0.54–1.83) 0.994 1.37 (0.75–2.48) 0.304
Model b 1.15 (0.61–2.19) 0.670 1.4 (0.72–2.58) 0.340
Crude = uncorrected data. Model a = crude data plus adjustment for age and gender. Model b = model a plus adjustment for markers of disease 
activity/severity (disease duration, erythrocyte sedimentation rate levels, and health assessment questionnaire). CI, confidence interval; LD/LTE, 
low-dose/long-term exposure; MD/LTE, moderate-dose/long-term exposure; NCEP III, National Cholesterol Education Programme III; OR, odds 
ratio.Available online http://arthritis-research.com/content/10/6/R145
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ever, to ensure that disease activity per se (rather than ESR
alone) did not alter the results, the model was repeated includ-
ing DAS instead of ESR. Despite this, no significant associa-
tion was found between LE (OR = 1.189, P = 0.601) or ME
(OR = 1.453, P = 0.262) and the metabolic syndrome.
Discussion
This cross-sectional observational study has demonstrated
that long-term exposure to GCs, particularly at medium doses,
is associated with increased prevalence of two of the compo-
nents of the metabolic syndrome (high TG and hypertension),
but not any of the other components (low HDL, obesity, and
glucose intolerance) or the presence of the metabolic syn-
drome itself. We have presented data having used the NECP
III criteria for metabolic syndrome as they are the most up-to-
date and widely used, allowing comparison of our results with
those of other studies in RA and other conditions. However,
for the purpose of completeness, we have also analysed the
data on the basis of other metabolic syndrome classification
criteria, including those of the World Health Organisation [34],
the International Diabetes Federation [35], and the European
Group for the Study of Insulin Resistance [36], in order to
ensure that the definition used would not affect the outcome
of this study. The lack of any association between GC expo-
sure and the presence of the metabolic syndrome in this RA
cohort was present irrespective of the metabolic syndrome cri-
teria used (data not shown).
Although no statistically significant association between GC
exposure and the metabolic syndrome was found, the multivar-
iate analysis did demonstrate a trend in the OR as steroid
exposure increased (LE 1.13 (0.62 to 2.04) versus ME 1.64
(0.92 to 2.92)). Thus, a possible limitation of the present study
may be that, despite the fact that it is by far the largest to date
to assess metabolic syndrome in RA, its power may not have
been sufficient to detect such an association, although the
clinical significance of such a weak association would then
come into question. The most important limitation of this study,
however, is its cross-sectional design, which does not allow
definitive interpretation of the causality and directionality of the
associations found. Notwithstanding these limitations, this
study has addressed an original question that has not been
addressed elsewhere in the literature in a large, very well-char-
acterised RA population, with prospective data collection,
thus allowing adjustment for many potential confounders and
minimising selection and recall bias or missing values, which
are all common problems in retrospective studies.
The absence of a relationship between long-term GC use and
the presence of the metabolic syndrome may be explained by
physical and metabolic changes occurring as part of the dis-
ease process or as an indirect consequence of treatments
other than steroids [37-39]. It is possible that the beneficial
effects produced by suppressing the impact of inflammation
on the metabolic syndrome may outweigh the harmful effects
of GCs. For example, in RA, many components of the lipid pro-
file are suppressed by the ongoing inflammatory burden,
including HDL [40]. However, suppression of the inflammatory
load via drug use (for example, DMARDs) produces a signifi-
cant increase in lipid levels, particularly HDL [41]. Conversely,
it may be that patients with RA have significantly modified their
risk factors for the metabolic syndrome as a consequence of
inflammation and that the addition of GC use cannot worsen
these further.
Central obesity is associated with increased cardiovascular
risk and is one of the components of the metabolic syndrome.
GC use has been shown to redistribute body fat and result in
central obesity with relative sparing of the extremities [42].
Long-term GC use can also be complicated by the develop-
ment of a steroid-induced myopathy [37-39,43], which may
further exacerbate the imbalance between fat mass and mus-
cle bulk. Although steroid myopathy primarily manifests with
proximal muscle weakness in the absence of muscle atrophy
[44], muscle wasting may occur as a consequence of a reduc-
tion in functional capacity. The systemic inflammation associ-
ated with RA causes a hypercatabolic state, which, together
with a sedentary lifestyle, results in a loss of muscle bulk and
an increased tendency to gain fat in the presence of stable or
even slightly decreased weight, often referred to as rheuma-
toid cachexia [45]. It has been reported that almost two thirds
of patients with RA have features of rheumatoid cachexia [46],
and a recent study has demonstrated the need for redefining
the body mass index in RA to take into account these changes
[33]. It is therefore possible that, in RA patients, alterations in
body fat/muscle may have already occurred as part of the dis-
ease process and thus any additional changes that are
induced by long-term GC exposure may be insignificant. Alter-
natively, better control of inflammation due to steroid usage
may counterbalance some of the body composition abnormal-
ities that would have otherwise occurred. The latter possibility
would be supported by our findings in RA patients treated with
anti-TNF biologics [47].
A relationship between RA and abnormalities in the lipid profile
has been observed for several decades [48], with the key con-
tributing factor thought to be inflammation [49]. The typical
pattern of dyslipidaemia seen in active RA is a reduction in
total cholesterol, low-density lipoprotein, and HDL [40]. Data
regarding TG levels in RA are conflicting, with some studies
reporting an increase [50] and others a decrease [51]. The
metabolic syndrome definition takes in to account only two
components of the lipid profile, TG and HDL. GC use, inde-
pendent of dose, has been shown to increase HDL levels [52-
54]. Endogenous GC hormones regulate HDL plasma con-
centrations by increasing synthesis and secretion by the liver
[55]. Consequently, high doses of exogenous GCs such as
those being received by RA patients are likely to accelerate
this pathway. Therefore, in RA, HDL levels previously sup-
pressed by disease activity will rise, producing a less athero-Arthritis Research & Therapy    Vol 10 No 6    Toms et al.
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genic profile. This was reflected in our study, in which an
increase in HDL levels was seen in patients receiving long-
term GCs (P = 0.011). The observed rise in HDL levels may
also be explained by the indirect effects of GCs. Patients
requiring GCs as part of their disease management are likely
to have aggressive disease, which contributes to a reduction
in mobility as a result of joint stiffness and damage. Therefore,
GC use in this subset of patients may result in suppression of
disease activity and allow patients to lead a more active life-
style with a further beneficial effect on HDL levels [56].
Elevation of TG levels in patients receiving GCs on a long-term
basis has also been demonstrated [57,58]. However, many of
the studies have been limited due to the lack of control for
other potential lipid-influencing factors such as metabolic,
nutritional, or comorbid conditions. Although the proportion of
patients fulfilling the NCEP III-specified cut off levels for TGs
was significantly higher in the group receiving long-term GCs
in this study (P  = 0.026), this alone was not sufficient to
impact significantly on the overall prevalence of the metabolic
syndrome, possibly being counterbalanced by increases in
HDL, producing an overall less atherogenic lipid profile.
Shortly after the discovery of GC by Hench and colleagues
[59] in 1948, it became apparent that patients were frequently
developing adverse effects, including hypertension and diabe-
tes [60]. Despite this, there is limited evidence to support
these initial observations. In the general population, studies
attempting to assess the association between GC use and
hypertension have been hampered by poor study design [61],
thus resulting in a distinct lack of direct evidence to support
this relationship. In RA, this association has been studied in
more detail, with two recent studies demonstrating an
increase in blood pressure in patients treated with long-term
medium-dose ( 7.5 mg) GC [12,62]. One of these studies, a
large cross-sectional study, confirmed an association inde-
pendent of other risk factors for hypertension and RA disease
activity or severity [12]. Although it appears that there is a link
between GC exposure and hypertension in RA, it has also
been speculated that RA itself may predispose patients to an
increased prevalence of hypertension [63]. The data pro-
duced in the present study show a significant increase in the
numbers of patients fulfilling the NCEP III-specified cut off lev-
els for hypertension (= 130/85 mm Hg or taking anti-hyperten-
sives) in those receiving long-term GC. It may be that, despite
hypertension being prevalent in RA, there is still scope for fur-
ther modification through the actions of GCs. Irrespective of
this, it appears again that the increased frequency of patients
satisfying both the hypertensive and hypertrigylceridaemic
components of the metabolic syndrome in the steroid-treated
group is not sufficient to also increase the frequency of those
qualifying for a diagnosis of the metabolic syndrome.
GC-induced hyperglycaemia is a well-recognised complica-
tion of long-term GC use [64]. It is known that patients with
active RA have impaired glucose handling and that glucose
metabolism may be affected directly or indirectly by inflamma-
tory mediators [65]. Several studies have demonstrated an
association between GC use and decreased insulin sensitivity
[10,66,67]. However, there is smaller bank of conflicting data
demonstrating that GC use in RA paradoxically restores glu-
cose handling to normal whilst also inducing hyperinsulinism
[68]. In the present RA population, it is possible that GC use
restored glucose handling to normal via anti-inflammatory
mechanisms, hence explaining why this component was not
significant in the univariate analysis and had no impact on the
frequency of the metabolic syndrome.
Conclusion
In summary, this study suggests that the presence of the met-
abolic syndrome in RA appears to be independent of the use
of GCs. It is possible that the disease process itself is the key
contributor. This would suggest that effective management of
metabolic syndrome in RA is likely to require a two-pronged
approach: identification and management of individual classi-
cal risk factors, particularly hypertension and hypertriglyceri-
daemia, as well as aggressive control of inflammatory disease
activity with available means, including judicious usage of
GCs.
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